Zhejiang Orient Gene Biotech Co.,Ltd

Equities

688298

CNE100003RM8

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-07-16 EDT			5-day change	1st Jan Change
25.52 ^CNY	+1.67%		+2.08%	-28.64%

07-03	Tranche Update on Zhejiang Orient Gene Biotech Co.,Ltd's Equity Buyback Plan announced on February 8, 2024.	CI
06-12	US FDA Grants Emergency Use Authorization to Orient Gene Biotech's COVID-19 Test Kit	MT

Tranche Update on Zhejiang Orient Gene Biotech Co.,Ltd's Equity Buyback Plan announced on February 8, 2024.

July 02, 2024

From February 7, 2024 to March 31, 2024, the company has repurchased 8,332,700 shares, representing 4.13% for CNY 275 million. With this, the company has completed the repurchase of 8,332,700 shares, representing 4.13% for CNY 275 million under the buyback announced on February 8, 2024.

Latest news about Zhejiang Orient Gene Biotech Co.,Ltd

Tranche Update on Zhejiang Orient Gene Biotech Co.,Ltd's Equity Buyback Plan announced on February 8, 2024.	07-02	CI
US FDA Grants Emergency Use Authorization to Orient Gene Biotech's COVID-19 Test Kit	06-12	MT
Orient Gene Biotech's US Unit Gets FDA Clearance for Fentanyl Detectors	05-16	MT
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Zhejiang Orient Gene Biotech's Unit Gets US FDA's Nod to Register Two Products	04-23	MT
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Zhejiang Orient Gene Biotech Co.,Ltd announces an Equity Buyback for CNY 100 million worth of its shares.	02-07	CI
Zhejiang Orient Gene Biotech Co.,Ltd authorizes a Buyback Plan.	02-06	CI
Zhejiang Orient Gene Obtains Veterinary GMP Certificate, Production License	01-08	MT
Zhejiang Orient Gene Biotech Co.,Ltd(SHSE:688298) dropped from Shanghai Stock Exchange Health Care Sector Index	12-08	CI
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Orient Gene Biotech Registers New In Vitro Diagnostic Reagents	23-07-13	MT
Zhejiang Orient Gene Biotech Elects Chairman, Vice Chairman	23-06-01	MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Zhejiang Orient Gene Registers Two Medical Devices in EU, US	23-03-24	MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
IN BRIEF: Omega Diagnostics receives CD4 deferred consideration	22-11-25	AN
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Omega Diagnostics Up 16% With Sale Of Loss-Making CD4 Business	22-08-03	MT
ZXBio, Inc. announced that it has received $3.1 million in funding from Zhejiang Orient Gene Biotech Co., Ltd.	22-06-07	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Omega Diagnostics Shares Plunge on $1.4 Million Sale of Loss-making Business to Chinese Biotech	22-02-11	MT

Chart Zhejiang Orient Gene Biotech Co.,Ltd

Duration

Period

Chart Zhejiang Orient Gene Biotech Co.,Ltd

More charts

Company Profile

Zhejiang Orient Gene Biotech Co., Ltd. is a China-based company principally involved in the research, development, manufacture and sales of in-vitro diagnostic products. The Company's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The Company also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The Company operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
ZHEJIANG ORIENT GENE BIOTECH CO.,LTD	-28.64%	697M
BIOMÉRIEUX	-6.61%	12.07B
LANTHEUS HOLDINGS, INC.	+94.54%	8.2B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-18.38%	6.59B
DIASORIN S.P.A.	+9.13%	5.89B
AUTOBIO DIAGNOSTICS CO., LTD.	-21.66%	3.47B
ANDON HEALTH CO., LTD.	+5.36%	2.52B
MYRIAD GENETICS, INC.	+42.58%	2.48B
VITROLIFE AB	+17.72%	2.3B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-18.43%	1.58B

Diagnostic & Testing Substances